Big Pharma Paradoxes (BPP): Selling simultaneously drugs which Induce and Treat melanomas: "The simple example for complicated Relations!"

Georgi Tchernev¹,²* and Ivanka Temelkova¹,²

¹Department of Dermatology, Venereology and Dermatologic surgery, Medical Institute of Ministry of Interior [MVR]; Sofia, Bulgaria
²Onkoderma- Clinic for Dermatology, Venereology and Dermatologic Surgery; Sofia, Bulgaria

Received: July 29, 2019; Accepted: July 31, 2019; Published: August 1, 2019

*Corresponding author: Prof. Dr. Georgi Tchernev, Department of Dermatology, Venereology and Dermatologic Surgery, Medical Institute of Ministry of Interior [MVR], General Skobelev 79, 1606 Sofia, Bulgaria, E-mail: georgi_tchernev@yahoo.de

Again we would like to focus the attention to a case of valsartan induced melanoma: a patient who has received two medical products (combined drug of amlodipine and valsartan 10/160mg [1-0-0], in the period 2008 to 2018, and additional valsartan 160mg [0-0-1] from 2015 that 1) the suspected primary melanocytic lesion was acquired one and occurred about three years after the start of the treatment with two different sartans 2) progression to cutaneous melanoma was observed when the dose of the valsartan was doubled within a period of 2.5 years, and 3) the exact application of the guidelines of AJCC for surgical treatment of cutaneous melanoma does not protect from melanoma progression (as in the case described by us) unlike the OSMS surgical model in which this progression is absent [3,4].

Analysis of these facts reveals possible or at least at some type of art hypothetical links between cancer development/carcinogenesis generation and melanoma treatment [1,2]? The role of the so-called "Big Pharma" should not be immediately ignored with a "light hand", and the reasons for that are the FDA/EMA notifications and the behavior of the Big Pharma in this scandal: 1) sartans are carcinogenic (stated by the FDA/EMA), 2) a 6-month grace period is given, so that the production of all companies is "cleared" from possible carcinogenic substances, and 3) not all European companies are screened for carcinogenic ingredients, although there is clinical data for such a connection: drugs, produced in Europe, not sanctioned and even not checked [1,3,4].

One of the main reasons for the resistance in pharmaceutical and some medical circles about the introduction of this model for surgical behavior –OSMS, is the goal of breaking the mentioned vicious circle.

Another key point is the one step melanoma surgery model (OSMS) which we have introduced in other cases of drug induced melanomas that fill the preferred recommendations without an evidence for metastatic disease at the time of the initial diagnosis establishment [3,4].

We have presented two additional cases of patients with drug induced cutaneous melanomas successfully treated with the OSMS model with absence of any data for recurrence in the two years of follow up period [3,4].

One step melanoma surgery should be the possible solution that minimises the possibility of mistakes and hence prevents the possibility of melanoma progression [3,4]. It is precisely because...
of this fact, that it should be noted that the introduction of OSMS as a standard for the treatment of several/some or selected melanoma patients would result in a reduction of patients reaching stages III or IV where the drugs mentioned above are being used.

References
6. Exforge Prices, Coupons and Patient Assistance Programs.